Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/34372
Tüm üstveri kaydı
Dublin Core Alanı | Değer | Dil |
---|---|---|
dc.contributor.author | Çetinkaya, Merih | - |
dc.date.accessioned | 2023-10-16T08:24:47Z | - |
dc.date.available | 2023-10-16T08:24:47Z | - |
dc.date.issued | 2015-10-05 | - |
dc.identifier.citation | Koyuncuoğlu, T. vd. (2015). "Uridine protects against hypoxic-ischemic brain injury by reducing histone deacetylase activity in neonatal rats". Restorative Neurology and Neuroscience, 33(5), 777-784. | en_US |
dc.identifier.issn | 0922-6028 | - |
dc.identifier.uri | https://content.iospress.com/articles/restorative-neurology-and-neuroscience/rnn150549 | - |
dc.identifier.uri | https://doi.org/10.3233/RNN-150549 | - |
dc.identifier.uri | http://hdl.handle.net/11452/34372 | - |
dc.description.abstract | Purpose: A significant cause of neurological disability in newborns is hypoxic-ischemic encephalopathy (HIE), a disorder which involves an enhancement in histone deacetylase (HDAC) activity among underlying pathological mechanisms. We showed recently that exogenous administration of uridine to newborn rats with HIE reduced brain injury in a dose-dependent manner. The present study was performed to investigate whether uridine modulates histone acetylation/deacetylation balance in a neonatal rat model of HIE. Methods: Newborn rats that were subjected to hypoxic-ischemic (HI) insult on postnatal day 7 (P7) were injected intraperitoneally with either saline or uridine (500 mg/kg) for three consecutive days. One day after completion of treatment, brains of pups were collected for evaluation of brain infarct volume, apoptosis, HDAC activity and acetylated-Histone H3 (Ac-H3) and H4 (Ac-H4) protein levels. Results: Results revealed that uridine administration reduced infarct volume, active Caspase-3 levels and HDAC activity while increasing the expressions of Ac-H3 and Ac-H4 proteins. Conclusions: We conclude that one mechanism by which uridine provides neuroprotection in neonatal rat HIE model involves reduction in HDAC activity. | en_US |
dc.language.iso | en | en_US |
dc.publisher | IOS Press | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject | Hypoxic-ischemic encephalopathy | en_US |
dc.subject | Neonatal | en_US |
dc.subject | Rat | en_US |
dc.subject | Uridine | en_US |
dc.subject | Histone deacetylase | en_US |
dc.subject | Neuroprotection | en_US |
dc.subject | Docosahexaenoic acid | en_US |
dc.subject | CDP-choline | en_US |
dc.subject | Inhibition | en_US |
dc.subject | Model | en_US |
dc.subject | Combination | en_US |
dc.subject | Damage | en_US |
dc.subject | Neurodegeneration | en_US |
dc.subject | Neuroprotection | en_US |
dc.subject | Mechanisms | en_US |
dc.subject | Receptors | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Animals, newborn | en_US |
dc.subject.mesh | Blotting, western | en_US |
dc.subject.mesh | Brain | en_US |
dc.subject.mesh | Caspase 3 | en_US |
dc.subject.mesh | Disease models, animal | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Histone deacetylase inhibitors | en_US |
dc.subject.mesh | Histone deacetylases | en_US |
dc.subject.mesh | Hypoxia-ischemia, brain | en_US |
dc.subject.mesh | Injections, intraperitoneal | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Neuroprotective agents | en_US |
dc.subject.mesh | Random allocation | en_US |
dc.subject.mesh | Rats, Sprague-Dawley | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.mesh | Uridine | en_US |
dc.title | Uridine protects against hypoxic-ischemic brain injury by reducing histone deacetylase activity in neonatal rats | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000362959900016 | tr_TR |
dc.identifier.scopus | 2-s2.0-84943759407 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Fizyoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Farmakoloji Anabilim Dalı. | tr_TR |
dc.relation.bap | KUAP(T)-2013/76 | tr_TR |
dc.contributor.orcid | 0000-0001-8061-8756 | tr_TR |
dc.contributor.orcid | 0000-0003-2918-5064 | tr_TR |
dc.contributor.orcid | 0000-0001-6466-5042 | tr_TR |
dc.identifier.startpage | 777 | tr_TR |
dc.identifier.endpage | 784 | tr_TR |
dc.identifier.volume | 33 | tr_TR |
dc.identifier.issue | 5 | tr_TR |
dc.relation.journal | Restorative Neurology and Neuroscience | en_US |
dc.contributor.buuauthor | Koyuncuoğlu, Türkan | - |
dc.contributor.buuauthor | Türkyımaz, Mesut | - |
dc.contributor.buuauthor | Gören, Bülent | - |
dc.contributor.buuauthor | Cansev, Mehmet | - |
dc.contributor.buuauthor | Alkan, Tülin | - |
dc.contributor.researcherid | O-9601-2015 | tr_TR |
dc.contributor.researcherid | EBA-0754-2022 | tr_TR |
dc.contributor.researcherid | AAH-1718-2021 | tr_TR |
dc.contributor.researcherid | M-9071-2019 | tr_TR |
dc.contributor.researcherid | AAH-1792-2021 | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.identifier.pubmed | 26410212 | tr_TR |
dc.subject.wos | Neurosciences | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q3 | en_US |
dc.contributor.scopusid | 57190272398 | tr_TR |
dc.contributor.scopusid | 56320252500 | tr_TR |
dc.contributor.scopusid | 6602543716 | tr_TR |
dc.contributor.scopusid | 8872816100 | tr_TR |
dc.contributor.scopusid | 6601953747 | tr_TR |
dc.subject.scopus | Histone deacetylases; Animals; Epigenetics | en_US |
dc.subject.emtree | Caspase 3 | en_US |
dc.subject.emtree | Histone deacetylase | en_US |
dc.subject.emtree | Histone H3 | en_US |
dc.subject.emtree | Histone H4 | en_US |
dc.subject.emtree | Sodium chloride | en_US |
dc.subject.emtree | Uridine | en_US |
dc.subject.emtree | Casp3 protein, rat | en_US |
dc.subject.emtree | Histone deacetylase inhibitor | en_US |
dc.subject.emtree | Neuroprotective agent | en_US |
dc.subject.emtree | Uridine | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Animal model | en_US |
dc.subject.emtree | Apoptosis | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Brain | en_US |
dc.subject.emtree | Brain infarction | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Deacetylation | en_US |
dc.subject.emtree | Enzyme activity | en_US |
dc.subject.emtree | Experimental model | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Histone acetylation | en_US |
dc.subject.emtree | Hypoxic ischemic encephalopathy | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Neuroprotection | en_US |
dc.subject.emtree | Newborn | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Rat | en_US |
dc.subject.emtree | Animal | en_US |
dc.subject.emtree | Disease model | en_US |
dc.subject.emtree | Drug effects | en_US |
dc.subject.emtree | Enzymology | en_US |
dc.subject.emtree | Hypoxia-ischemia, brain | en_US |
dc.subject.emtree | Intraperitoneal drug administration | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Randomization | en_US |
dc.subject.emtree | Sprague dawley rat | en_US |
dc.subject.emtree | Treatment outcome | en_US |
dc.subject.emtree | Western blotting | en_US |
Koleksiyonlarda Görünür: | Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.